Cargando…
Comparing outcomes and costs among warfarin-sensitive patients versus warfarin-insensitive patients using The Right Drug, Right Dose, Right Time: Using genomic data to individualize treatment (RIGHT) 10K warfarin cohort
Oral anticoagulant (OAC) therapy has been the main treatment approach for stroke prevention for decades. Warfarin is the most widely prescribed OAC in the United States, but is difficult to manage due to variability in dose requirements across individuals. Pharmacogenomics may mitigate risk concerns...
Autores principales: | Swanson, Kristi M., Zhu, Ye, Rojas, Ricardo L., St. Sauver, Jennifer L., Bielinski, Suzette J., Jacobsen, Debra J., Visscher, Sue L., Wang, Liewei, Weinshilboum, Richard, Borah, Bijan J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237006/ https://www.ncbi.nlm.nih.gov/pubmed/32428022 http://dx.doi.org/10.1371/journal.pone.0233316 |
Ejemplares similares
-
Personalizing Health Care—Is This the Right Time for Warfarin?
por: Ansell, Jack
Publicado: (2009) -
Participant perceived understanding and perspectives toward pharmacogenomics: Mayo Clinic Right Drug, Right Dose, Right Time (RIGHT) Protocol
por: Olson, Janet E., et al.
Publicado: (2017) -
Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases
por: Zhu, Ye, et al.
Publicado: (2019) -
Warfarin overactivity
por: Yamanel, L, et al.
Publicado: (2005) -
Is the use of warfarin becoming obsolete?
por: Haykal, Tarek, et al.
Publicado: (2021)